NCT03815318 - Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 21, 2019

Primary Completion Date

January 16, 2020

Study Completion Date

January 16, 2020

Conditions

Hemophilia A

Interventions

DRUG

Recombinant Human Coagulation FVIII

Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.

Trial Locations (1)

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin